A two-year study of the new cyclosporine formulation consupren in De Novo Renal transplant patients
WE have shown in a previous study that converting renal transplant recipients from regular Sandimmun (SIM) to the new cyclosporine A (CyA) formulation Consupren (CON) could be achieved safely with preservation of a good graft function, no added renal or extrarenal toxicity, and with significant cost...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , |
| Format: | article |
| Published: |
1998
|
| Online Access: | http://hdl.handle.net/10725/5284 http://dx.doi.org/10.1016/S0041-1345(98)01136-1 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php http://ku7rj9xt8c.scholar.serialssolutions.com/?sid=google&auinit=AG&aulast=Stephan&atitle=A+two-year+study+of+the+new+cyclosporine+formulation+Consupren+in+de+novo+renal+transplant+patients&id=doi:10.1016/S0041-1345(98)01136-1&title=Transplantation+proceedings&volume=30&issue=7&date=1998&spage=3563&issn=0041-1345 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | WE have shown in a previous study that converting renal transplant recipients from regular Sandimmun (SIM) to the new cyclosporine A (CyA) formulation Consupren (CON) could be achieved safely with preservation of a good graft function, no added renal or extrarenal toxicity, and with significant cost benefits. The present study extends the use of CON as a primary immunosuppressant drug utilized de novo in the immediate posttransplant period |
|---|